Drug intelligence / Profile preview

KFD1 + 3R-NC

Development stage: Unknown
Lead developer: Fudan University School of Pharmacy
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

KFD1 + 3R-NC is a combination prophylactic vaccine candidate developed for the prevention of coronavirus infections, specifically targeting SARS-CoV-2. The drug acts as an inhibitor of the SARS-CoV-2 spike (S) protein, aiming to block viral entry into host cells. It is administered as a nasal spray and has been evaluated in early-stage clinical studies for safety and immunogenicity. The vaccine was initially developed by Fudan University and remains in preclinical or very early clinical development stages[1][2].

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on KFD1 + 3R-NC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KFD1 + 3R-NC.

Explore the full profile